JP6621252B2 - 治療耐性がんに対する治療耐性低減剤 - Google Patents
治療耐性がんに対する治療耐性低減剤 Download PDFInfo
- Publication number
- JP6621252B2 JP6621252B2 JP2015122399A JP2015122399A JP6621252B2 JP 6621252 B2 JP6621252 B2 JP 6621252B2 JP 2015122399 A JP2015122399 A JP 2015122399A JP 2015122399 A JP2015122399 A JP 2015122399A JP 6621252 B2 JP6621252 B2 JP 6621252B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- csf
- cancer
- treatment
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003638 chemical reducing agent Substances 0.000 title claims description 18
- 208000016691 refractory malignant neoplasm Diseases 0.000 title claims description 18
- 238000011282 treatment Methods 0.000 title description 30
- 101710181549 Interleukin-34 Proteins 0.000 claims description 68
- 102100033499 Interleukin-34 Human genes 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 31
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 30
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 238000002512 chemotherapy Methods 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 75
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 50
- 239000012228 culture supernatant Substances 0.000 description 29
- 229960004679 doxorubicin Drugs 0.000 description 25
- 238000004113 cell culture Methods 0.000 description 21
- 210000001616 monocyte Anatomy 0.000 description 21
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 18
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 11
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 10
- 102100022338 Integrin alpha-M Human genes 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000004322 M2 macrophage Anatomy 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108010009992 CD163 antigen Proteins 0.000 description 8
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 8
- 102100025136 Macrosialin Human genes 0.000 description 8
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010059866 Drug resistance Diseases 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 2
- 208000004987 Macrophage activation syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 238000011577 humanized mouse model Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000998132 Homo sapiens Interleukin-34 Proteins 0.000 description 1
- 101150027225 Il34 gene Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000002580 human interleukin-34 Human genes 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
Description
(2)IL−34に結合することでIL−34とCSF−1Rとの結合を特異的に阻害する物質を有効成分とする、(1)に記載の治療耐性低減剤。
(3)IL−34に対する特異抗体を有効成分とする、(1)又は(2)に記載の治療耐性低減剤。
(4)抗がん剤投与治療又は放射線照射治療において併用するための、(1)〜(3)のいずれかに記載の治療耐性低減剤。
ヒト肺腺がん細胞株A549は、American Type Cell Culture(ATCC、USA)から入手した。細胞培養は、ウシ胎児血清(終濃度10%)、ペニシリン(終濃度100U/mL)及びストレプトマイシン(終濃度100μg/mL)を加えたダルベッコ変法イーグル培地(DMEM)(SIGMA)を用いて、37℃、5%CO2下で行った。DOX濃度を0.01〜1μMまで段階的に上昇させたDMEM中でA549細胞を37℃、5%CO2下で培養し、DOX耐性を獲得した細胞を選抜することにより、DOX耐性A549細胞株(A549−DR)を作製した。得られたA549−DR細胞は、1μM DOXに曝露することで、その薬剤耐性を維持した。
上記1)で作製したA549−DR細胞を滅菌PBSで5回洗浄し、DOX非添加DMEM10mLを予め分注した細胞培養プレートに1×106個/mLとなるように播種し、72時間培養した後、培養上清を回収した。薬剤耐性を誘導していないA549細胞(A549−DS)の培養上清も同様に調製した。
マグネティックセルソーティングシステム(Miltenyi Biotech)を用いてヒト健常ドナーからCD14+単球を分離し、これを上記2)と同様にA549−DS又はA549−DR細胞の培養上清で刺激した。6〜7日後に単球を回収し、Sepazol(nacalai)で全RNAを抽出して、マクロファージマーカーとして知られるCD14、CD11b、CD68及びCD163の発現レベルをRT−PCRで測定した。RT−PCRは、表1に記載のプライマーセットを用いて、Power SYBR(登録商標) Green(Applied Biosystems)を使用して、製造業者のプロトコールに従って実施した。
上記3)の結果から、A549−DR細胞はM−CSFの分泌を介して単球をM2マクロファージに分化させるという仮説を立て、A549−DR細胞におけるM−CSF mRNAの発現をRT−PCRにより測定した。RT−PCRは、表1に記載のプライマーセットを用いて、上記3)と同様の方法で実施した。結果を図4に示す。仮説に反し、M−CSFのmRNA発現量は、A549−DSと比較してA549−DR細胞で低下していた。
薬剤耐性におけるIL−34の役割を解明するため、CRISPRシステムを利用してIL−34ノックアウトA549−DR細胞株(A549−DR−IL−34−KO)を作製した。具体的には、pCas−ガイドベクター中にIL−34のガイドRNAを組み込んだIL34−gene knockout kit via CRISPR,Human(−)(Origene)を、トランスフェクション試薬としてFuGENE(登録商標) 6 Transfection Reagent(Promega)を用いて、A549−DR細胞にトランスフェクトした。IL−34遺伝子のノックアウトは、RT−PCR及びELISAによりIL−34のmRNA及びタンパク質が検出されないことで確認した。
A549−DS細胞、A549−DR細胞、A549−DR−IL−34−KO細胞をDOX添加(終濃度1μM)DMEM培地又はDOX非添加DMEM培地で培養し、72時間後、MTTアッセイ(細胞増殖測定キット、ロシュアプライド)を行って細胞生存率を測定した。同様に、A549−DR細胞を、抗IL−34中和抗体を終濃度0.01〜10μg/mLで添加したDOX添加又は非添加培地で培養し、細胞生存率を同様に測定した。結果を図7に示す。
NOGマウス(NOD/Shi−Scid IL−2RγKO Jic、雌性、6週齢)にX線(2.5G)を照射し、24時間後にヒト骨髄細胞200万個(Stem cell technologies)を移植した。3週間後、マウスに1×106個のA549−DS細胞、A549−DR細胞、A549−DR−IL−34−KO細胞を接種し、腫瘍サイズが5mmに達したら(がん細胞接種から1週間後)、DOXを10mg/kg/マウスの用量で週に2回、合計4回、静脈内投与した。対照群には、DOXの代わりにPBSを同量投与した。試験終了後、摘出した腫瘍から単細胞懸濁液を調製し、これをanti−CD68、anti−CD163(メーカー名Biolegend)で染色し、FACS解析によりCD68+CD163+細胞の数を評価した。
Claims (3)
- インターロイキン−34に結合することでインターロイキン−34とコロニー刺激因子−1受容体との結合を特異的に阻害するインターロイキン−34に対する特異抗体、又は当該特異抗体のインターロイキン−34への特異的結合能を有する断片を有効成分とする、治療耐性がんに対する治療耐性低減剤。
- がん細胞におけるインターロイキン−34の発現を抑制する阻害性核酸を有効成分とする、治療耐性がんに対する治療耐性低減剤。
- 化学療法、放射線療法及び/又は免疫療法において併用するための、請求項1又は2に記載の治療耐性低減剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015122399A JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
PCT/JP2016/067906 WO2016204216A1 (ja) | 2015-06-17 | 2016-06-16 | 治療耐性がんに対する治療耐性低減剤 |
EP16811690.3A EP3311840B1 (en) | 2015-06-17 | 2016-06-16 | Treatment-resistance reducing agent for treatment-resistant cancer |
US15/736,203 US20180193453A1 (en) | 2015-06-17 | 2016-06-16 | Treatment-resistance reducing agent for treatment-resistant cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015122399A JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017007956A JP2017007956A (ja) | 2017-01-12 |
JP2017007956A5 JP2017007956A5 (ja) | 2018-08-02 |
JP6621252B2 true JP6621252B2 (ja) | 2019-12-18 |
Family
ID=57545648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015122399A Active JP6621252B2 (ja) | 2015-06-17 | 2015-06-17 | 治療耐性がんに対する治療耐性低減剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20180193453A1 (ja) |
EP (1) | EP3311840B1 (ja) |
JP (1) | JP6621252B2 (ja) |
WO (1) | WO2016204216A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6356317B1 (ja) * | 2017-06-05 | 2018-07-11 | 国立大学法人北海道大学 | 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び/又は治療のための医薬 |
WO2020027217A1 (ja) * | 2018-07-31 | 2020-02-06 | 国立大学法人北海道大学 | がんの治療及び/又は予防のための医薬 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR080698A1 (es) * | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
NZ603193A (en) * | 2010-05-04 | 2014-07-25 | Five Prime Therapeutics Inc | Antibodies that bind csf1r |
CA2841013C (en) * | 2011-07-18 | 2020-04-21 | Morphosys Ag | Use of c-fms antagonists |
RU2014136332A (ru) * | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
ES2870983T3 (es) * | 2014-12-19 | 2021-10-28 | Univ Nantes | Anticuerpos anti-IL-34 |
PL3283527T3 (pl) * | 2015-04-13 | 2021-06-14 | Five Prime Therapeutics, Inc. | Leczenie skojarzone nowotworów |
-
2015
- 2015-06-17 JP JP2015122399A patent/JP6621252B2/ja active Active
-
2016
- 2016-06-16 US US15/736,203 patent/US20180193453A1/en not_active Abandoned
- 2016-06-16 WO PCT/JP2016/067906 patent/WO2016204216A1/ja active Application Filing
- 2016-06-16 EP EP16811690.3A patent/EP3311840B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3311840A4 (en) | 2019-02-27 |
US20180193453A1 (en) | 2018-07-12 |
WO2016204216A1 (ja) | 2016-12-22 |
EP3311840B1 (en) | 2021-09-29 |
EP3311840A1 (en) | 2018-04-25 |
JP2017007956A (ja) | 2017-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
de Mingo Pulido et al. | The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake | |
JP7223055B2 (ja) | 癌治療のための併用免疫療法及びサイトカイン制御療法 | |
JP7461449B2 (ja) | 治療用rna | |
Wang et al. | Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model | |
JP2022188225A (ja) | 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ | |
WO2021053667A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
JP7232447B2 (ja) | メモリー機能を有するt細胞又はb細胞の増強剤、悪性腫瘍再発抑制剤、及びt細胞又はb細胞にメモリー機能を誘導する誘導剤 | |
WO2016189532A1 (en) | Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes | |
JP2022092001A (ja) | 樹状細胞免疫療法 | |
US11788093B2 (en) | Chimeric antigen receptor t-cells expressing interleukin-8 receptor | |
US20220111069A1 (en) | Immunoswitch nanoparticles for reprogrammed t cell responses | |
CN108472317A (zh) | 修饰免疫细胞及其用途 | |
CN106574241A (zh) | 癌症免疫疗法组合物和方法 | |
US20180128833A1 (en) | Methods of treating with tumor membrane vesicle-based immunotherapy and predicting therapeutic response thereto | |
KR20220015375A (ko) | Sephb4-hsa 융합 단백질을 이용한 암의 치료 | |
JP6621252B2 (ja) | 治療耐性がんに対する治療耐性低減剤 | |
JP2020524141A (ja) | がんを処置するための方法および組成物 | |
EP4031655A2 (en) | Combination cancer therapy and cytokine control therapy for cancer treatment | |
Ajeawung et al. | Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas | |
US20190269729A1 (en) | Modified natural killer cells for the treatment of cancer | |
JP2019131505A (ja) | 抗がん剤 | |
JP7407452B2 (ja) | がんの治療及び/又は予防のための医薬 | |
JP2020510681A (ja) | 抗レナラーゼ抗体および抗pd−1抗体を用いる、がんを処置するための組成物および方法 | |
US20230257713A1 (en) | Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell | |
WO2024023827A1 (en) | Treatment of brain metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190904 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191029 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6621252 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |